Breast Tru-Cut Biopsy Report - Complete Explanation

Patient Overview

What is a Tru-Cut Biopsy?

Final Diagnosis (Impression)

Right breast biopsy - Malignant (B5b) - Invasive Ductal Carcinoma, Grade 2

• B5b is the radiological/pathological reporting category meaning "malignant - invasive." This is the most clinically significant classification, indicating definitive cancer requiring treatment.
• Invasive Ductal Carcinoma (IDC) is the most common form of breast cancer, also called "No Special Type" (NST). It arises from the ductal epithelium and invades the surrounding breast stroma.
• Grade 2 (Moderately differentiated): The Nottingham (Elston-Ellis modification of Scarff-Bloom-Richardson) grading system scores three features - tubule formation, nuclear pleomorphism, and mitotic count - each 1 to 3 points, summed for a total of 3-9. A score of 6 or 7 = Grade 2. Grade 2 tumors show moderate glandular differentiation with some pleomorphism and moderate mitotic activity. They sit between the favorable Grade 1 and aggressive Grade 3. - Mulholland and Greenfield's Surgery, p. 3933

Microscopic Findings - Explained

Tumor architecture: "Nests and cords in a desmoplastic stroma"

• Neoplastic cells growing in nests and cords indicates loss of normal glandular architecture - characteristic of invasive carcinoma.
• Desmoplastic stroma means the tumor has induced a dense fibrous/scirrhous reaction in the surrounding connective tissue. This is a hallmark of IDC and is why many breast cancers feel hard on palpation.

Cell characteristics: "Moderate eosinophilic cytoplasm and moderate pleomorphic nuclei"

• Eosinophilic cytoplasm: Cells stain pink with H&E stain, indicating moderate protein content.
• Moderate nuclear pleomorphism: Tumor nuclei are of variable size/shape - more than benign cells but less severe than Grade 3. This contributes to the Grade 2 designation.

"Few mitotic figures"

• Mitoses are cells caught in the act of division. "Few" mitotic figures corresponds to a lower mitotic score (1 of 3), consistent with Grade 2. High mitotic activity would push toward Grade 3.

"No lymphovascular invasion (LVI)"

• No cancer cells seen invading blood vessels or lymphatics. This is favorable - LVI is associated with higher risk of lymph node metastasis and distant spread.

"Microcalcification noted"

• Small calcium deposits within the tumor. These are commonly detected on mammography as clustered calcifications. In IDC, microcalcifications often form within areas of tumor necrosis or secretory activity and may be the initial mammographic finding that leads to biopsy.

Tumor Infiltrating Lymphocytes (TILs): 5-10%

• TILs represent the immune system's response to the tumor. A 5-10% TIL level is low-intermediate. Higher TILs (especially >50%) are a positive prognostic marker and predict better response to immunotherapy/chemotherapy in certain subtypes. In ER+/HER2- tumors like this one, TIL significance is more limited compared to triple-negative breast cancer.

Biomarker Results - Detailed Interpretation

Estrogen Receptor (ER) - POSITIVE

• Clone used: SP1 (a validated monoclonal antibody)
• >95% of cells show nuclear positivity
• Strong staining intensity
• Allred Score: 8/8 (maximum score)

Progesterone Receptor (PgR/PR) - POSITIVE

• Clone used: 1E2
• 85-90% of cells show nuclear positivity
• Weak to Moderate staining intensity
• Allred Score: 7/8

HER2/neu (by IHC, clone 4B5) - NEGATIVE (Score 1+)

• HER2 is human epidermal growth factor receptor 2 - a tyrosine kinase receptor.
• IHC Score 1+ = incomplete, faint membrane staining in >10% of cells. This is negative by ASCO/CAP guidelines (score 0 or 1+ = negative; 2+ = equivocal, needs FISH; 3+ = positive).
• HER2 negativity means the patient does not benefit from HER2-targeted drugs like trastuzumab (Herceptin). However, note that emerging data on "HER2-low" (score 1+) now identifies a potential subgroup who may benefit from newer antibody-drug conjugates (e.g., trastuzumab deruxtecan) - this should be discussed with the treating oncologist.

Ki-67 (MIB-1 clone) - 15-18%

• Ki-67 is a nuclear proliferation marker expressed in all active cell cycle phases (except G0/resting).
• 15-18% is borderline-high. By consensus:
  • <14% = Low proliferative index (Luminal A)
  • 14-20% = Intermediate/borderline

  • 20% = High proliferative index

• Ki-67 of 15-18% falls in the borderline zone - not clearly low, not clearly high. This is an important distinction for molecular subtype classification.

Molecular Subtype Classification

• Luminal A: ER+/PR+, HER2-, Ki-67 <14% - slower growing, best prognosis
• Luminal B (HER2-): ER+ and/or PR+, HER2-, Ki-67 ≥14% - faster growing than Luminal A, moderately aggressive

Fixation and Quality Control

• Cold ischaemia and fixation times meet ASCO/CAP guidelines (>6 hrs, <72 hrs formalin fixation).
• This is important because inadequate fixation can cause false-negative receptor results. The explicit statement here validates the reliability of the ER, PR, and HER2 results.
• External controls for ER and PR are confirmed present - this is standard quality assurance.

Summary of Clinical Significance

Likely Treatment Implications (for discussion with the oncologist)

1. Endocrine therapy is the cornerstone - aromatase inhibitor (e.g., letrozole) given she is post-menopausal (82 years).
2. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy have become standard for ER+/HER2- breast cancer - current standard of care evidence supports this.
3. Chemotherapy decision - the borderline Ki-67 (15-18%) and Grade 2 may prompt genomic testing (e.g., Oncotype DX Recurrence Score) to clarify whether chemotherapy adds benefit beyond hormone therapy alone.
4. Surgical planning - the next step will typically involve assessment of tumor size (imaging), lymph node status (sentinel node biopsy), and decision between lumpectomy and mastectomy.
5. Radiation - generally recommended after breast-conserving surgery.

TNM Staging for This Biopsy

The core limitation: Biopsy ≠ Complete Staging

• T (Tumor size) - measured on imaging (ultrasound/mammogram) or surgical excision
• N (Nodes) - sentinel lymph node biopsy or axillary dissection
• M (Metastasis) - CT scan chest/abdomen/pelvis, bone scan, or PET-CT

Full AJCC 8th Edition TNM Framework

T - Primary Tumor

For this patient: The cores were 12-15 mm (biopsy core length, NOT tumor size). Actual tumor dimensions must come from imaging (mammogram/ultrasound). The tumor could be T1 or T2 depending on imaging findings.

N - Regional Lymph Nodes

For this patient: The biopsy report states "No lymphovascular invasion" - this is favorable but does not confirm N0 (LVI is intratumoral, not lymph node status). Lymph node status requires sentinel lymph node biopsy.

M - Distant Metastasis

In an 82-year-old with de novo presentation, staging imaging is required to confirm M0.

Anatomic Stage Groups (AJCC 8th Ed.)

What Stage is MOST LIKELY for This Patient?

Most probable range: Stage I to Stage IIA

AJCC 8th Ed. Prognostic Stage (incorporates biomarkers)

• A T1cN0M0 (anatomic Stage I), Grade 2, ER+, PR+, HER2- tumor = Pathologic Prognostic Stage IA
• A T2N0M0 (anatomic Stage IIA), same biomarkers = Pathologic Prognostic Stage IB (downstaged by favorable biology)

What Needs to be Done to Complete Staging

1. Bilateral mammogram + ultrasound - measure exact tumor size (T classification)
2. Sentinel lymph node biopsy (at time of surgery) - confirm N status
3. Staging CT scan (chest/abdomen/pelvis) and/or bone scan - confirm M0 in a symptomatic 82-year-old
4. Potentially Oncotype DX - genomic recurrence score to guide chemotherapy decision in ER+/HER2-/N0 disease

Bottom Line

Chemotherapy vs. Hormonal (Endocrine) Therapy - Explained Simply

Part 1: What is Chemotherapy?

The Simple Idea

How it Works

• Damage the cancer cell's DNA so it cannot copy itself (e.g., doxorubicin/Adriamycin)
• Disrupt the spindle fibres that pull chromosomes apart during division, freezing the cell mid-split (e.g., paclitaxel, docetaxel - the "taxanes")
• Block enzymes the cell needs to build new DNA (e.g., 5-fluorouracil, methotrexate)

The Catch - Side Effects

• Hair follicles → hair loss
• Gut lining → nausea, vomiting, diarrhea
• Bone marrow → low blood counts (anemia, infection risk, bleeding)
• Mouth lining → mouth sores

Common Chemo Regimens for Breast Cancer (like this patient's type)

Is Chemotherapy Needed for THIS Patient?

• Hormonal therapy is the primary treatment
• Chemotherapy is not automatically given - it depends on:
  • Tumor size (T stage)
  • Lymph node involvement
  • Ki-67 (her 15-18% is borderline)
  • Oncotype DX score (a genomic test that predicts whether chemo adds benefit over hormones alone)

If her Oncotype DX recurrence score comes back low (<26), she can safely skip chemotherapy and just receive hormonal therapy. If high (≥26), chemo is added. Given her age of 82, the treating team will also weigh whether her body can tolerate chemotherapy at all.

Part 2: What is Hormonal (Endocrine) Therapy?

The Simple Idea

The Three Main Approaches

Drug 1: Tamoxifen (SERM - Selective Estrogen Receptor Modulator)

• How it works: Tamoxifen enters the breast cancer cell and sits inside the estrogen receptor like a key in a lock - but it does not turn the lock. It blocks estrogen from binding, so the "grow" signal is never sent.
• Who gets it: Mainly premenopausal women and men with breast cancer. Also used in postmenopausal women if aromatase inhibitors are not tolerated.
• Dose: 20 mg/day by mouth, for 5-10 years
• Proven benefit: Reduces breast cancer mortality by about one-third over 15 years; also cuts the risk of cancer in the other breast by 39%
• Side effects: Hot flashes, joint pain, nausea - and importantly, a small increased risk of uterine (endometrial) cancer and blood clots in postmenopausal women (because tamoxifen has a weak estrogen-like effect in the uterus even while blocking it in the breast) - Schwartz's Principles of Surgery, 11th Ed.

Drug 2: Aromatase Inhibitors (AIs) - THE choice for this patient

• How it works: In postmenopausal women (like Mrs. Narula, aged 82), the ovaries no longer make estrogen. Instead, estrogen is made in fat tissue, muscle, and the adrenal glands by an enzyme called aromatase, which converts androgens (male hormones) into estrogen. Aromatase inhibitors completely block this enzyme, cutting estrogen levels by over 95%.
• The three approved drugs:

• Who gets it: Postmenopausal women - this is first-line and preferred over tamoxifen in this group. They reduce recurrence rates by ~30% more than tamoxifen.
• Duration: Typically 5 years, sometimes extended
• Side effects: Joint/muscle aches (arthralgias - very common), hot flashes, osteoporosis/fractures (because estrogen normally protects bone), vaginal dryness

For Mrs. Narula (82 years, certainly postmenopausal): An aromatase inhibitor like letrozole is the expected first-line hormonal treatment. - Goldman-Cecil Medicine

Drug 3: CDK4/6 Inhibitors - The Modern Addition

• How it works: Cancer cells use proteins called CDK4 and CDK6 to push the cell through its division cycle. CDK4/6 inhibitors apply the brakes on cell division - they block these proteins, trapping cancer cells in a resting state (G1 phase) where they cannot replicate.
• The three drugs:
  • Palbociclib (Ibrance)
  • Ribociclib (Kisqali)
  • Abemaciclib (Verzenio)
• How they are used: Always combined with an aromatase inhibitor (not used alone)
• Proven benefit: Adding abemaciclib to an aromatase inhibitor provides additional survival benefit in high-risk early breast cancer
• Side effects: Low white blood cell counts (neutropenia), fatigue, diarrhea (especially abemaciclib)

Drug 4: Fulvestrant (SERD - Selective Estrogen Receptor Degrader)

• How it works: Instead of just blocking the estrogen receptor (like tamoxifen), fulvestrant completely destroys the receptor itself - the cancer cell loses its estrogen receptor entirely
• Given as: Monthly injection
• Used mainly in: Metastatic or advanced breast cancer, or when other hormonal therapies stop working

Summary: Chemo vs. Hormonal Therapy - Side by Side

What This Means for Mrs. Narula Specifically

• Hormonal therapy will be highly effective for her
• An aromatase inhibitor (letrozole/anastrozole) is the expected backbone of treatment
• A CDK4/6 inhibitor may be added if deemed high risk
• Chemotherapy may be avoidable - the genomic recurrence score (Oncotype DX) will help decide

TNM Stage - Now We Can Answer This Properly

What the Mammography Report Tells Us

TNM Breakdown

T - Tumor Size: T2

Important note about skin thickening/retraction: The report mentions associated skin thickening and retraction. Skin retraction alone (nipple/skin pulling inward due to fibrous desmoplastic reaction) does not automatically upgrade to T4. T4 requires actual invasion of the dermis/skin (ulceration, peau d'orange, macroscopic skin nodules) or chest wall extension. Skin retraction on mammography is a sign of the tumor's desmoplastic stroma pulling the skin inward - common in IDC - but is not itself T4 unless there is confirmed dermal invasion. This needs clinical correlation by the surgeon.

N - Lymph Nodes: cN0 (clinical)

• Mammogram: "No significant axillary lymphadenopathy seen"
• Biopsy: "No lymphovascular invasion"
• The 12 x 12 mm lesion in the axillary tail is a separate breast mass (BIRADS 4), not an axillary lymph node - it sits in the breast tissue extending into the axillary tail, not within the axillary lymph node chain

cN0 = No clinical/radiographic lymph node metastasis. This must be confirmed by sentinel lymph node biopsy at surgery (which will give a pN - pathologic N).

M - Metastasis: M0 (presumed)

• No distant metastases mentioned on mammogram
• Staging CT and bone scan have not been reported yet - these are still required to confirm M0 definitively in a symptomatic elderly patient

Final TNM Stage

Anatomic Stage (AJCC 8th Edition)

Prognostic Stage (AJCC 8th Ed. - includes biomarkers)

• Grade 2
• ER positive
• PR positive
• HER2 negative

The Second Lesion - Right Axillary Tail (BIRADS 4, 12 x 12 mm)

1. A satellite tumor deposit (multifocal/multicentric breast cancer - second focus in same breast) - if confirmed malignant, this does NOT change the N stage but may affect surgical planning (wider excision or mastectomy)
2. An intramammary lymph node with metastasis - which would upgrade N to N1
3. A benign lesion - fibroadenoma, lymph node, etc.

Summary